pharma · Tuberculosis · Meningococcal Meningitis
CanSino Biologics
CanSino Biologics is a pharma organization headquartered in CN. Primary therapeutic focus areas include Tuberculosis, Meningococcal Meningitis, Poliomyelitis. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s)
Tianjin, CN HQ
2009 Founded
138 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Tianjin, CN
- Founded
- 2009
- Employees
- 138
- Programs
- 3
- Drugs
- 9
- Patents
- 0
batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)
Phase 3 · mab · Meningococcal Meningitis
batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4) for Meningococcal Meningitis is a Phase 3 program (mab) at CanSino Biologics with 1 ClinicalTrials.gov record(s).
Internal code CTP-MCVF-006
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CanSino Biologics
- Phase
- Phase 3
- Modality
- mab
- Indication
- Meningococcal Meningitis
- Status
- active
- Trials
- 1